UMIN-CTR Clinical Trial

Recruitment status Preinitiation
Unique ID issued by UMIN UMIN000037715
Receipt No. R000043015
Scientific Title The safety and efficacy of AZM eye drops on MGD
Date of disclosure of the study information 2019/09/09
Last modified on 2019/08/17 (Ver. 1)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title The safety and efficacy of azimycin 1% eye drops on patients with posterior blepharitis
Acronym The efficacy of azimycin eye drops on patients with posterior blepharitis
Scientific Title The safety and efficacy of AZM eye drops on MGD
Scientific Title:Acronym The efficacy of AZM eye drops on MGD
Region
Japan

Condition
Condition posterior blepharitis
Classification by specialty
Ophthalmology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To evaluate the safety and efficacy of AZM eye drops on patients with meibomian gland dysfunction (MGD) (posterior blepharitis)
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Ocular symptom, lid margin abnormalities, tear film breakup time, lipid layer thickness, non-invasive tear film breakup time, tear osmolarity, meiboscore
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Single blind -investigator(s) and assessor(s) are blinded
Control Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 azimycin eyed drop plus warming eyelid
Interventions/Control_2 warming eyelids
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1) 18 years old older
2) both gender
3) informed consent available
4) those who were diagnosed with obstructive MGD
5) those who were diagnosed with seborrheic MGD
6) Ocular symptoms
7) lid margin abnormalities
8) plugging
Key exclusion criteria 1) Stevens-Johnson syndrome
2) acute inflammation
3) lid margin abnormalities
4) allergy
5) CL wear
6) Ocular surgery history within 3 monmths
7) systemic dieseases which might interfere with tear function
8) inappropriate charater
9) ocular diseases except cataract and/or refractive error
Target sample size 100

Research contact person
Name of lead principal investigator
1st name Reiko
Middle name
Last name Arita
Organization Itoh Clinic
Division name Ophthalmology
Zip code 3370042
Address Saitama City
TEL 0486865588
Email ritoh@za2.so-net.ne.jp

Public contact
Name of contact person
1st name Reiko
Middle name Arita
Last name Arita
Organization Itoh Clinic
Division name Ophthalmology
Zip code 3370042
Address 626-11, Minaminakano, Minuma-ku
TEL +81486865588
Homepage URL
Email ritoh@za2.so-net.ne.jp

Sponsor
Institute Itoh Clinic
Institute
Department

Funding Source
Organization Lid and meibomian gland working group
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Itoh Clinic
Address 626-11, Minaminakano, Minuma-ku
Tel 0486865588048
Email ritoh@za2.so-net.ne.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2019 Year 09 Month 09 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Preinitiation
Date of protocol fixation
2019 Year 08 Month 05 Day
Date of IRB
Anticipated trial start date
2019 Year 09 Month 09 Day
Last follow-up date
2020 Year 12 Month 30 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2019 Year 08 Month 17 Day
Last modified on
2019 Year 08 Month 17 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043015